⚠ Data freshness notice: the most recent refresh of NHTSA was incomplete, so a
very recent recall may be missing. Everything shown is accurate as of the last checked time on this page —
for anything time-critical, confirm with the official sources linked below.
FDAClass II · Drug · Recalled May 6, 2026
Optase Dry Eye Intense Drops (Glycerin 0 recall — SCOPE HEALTH
Hazard: Lack of Assurance of Sterility
Class II: may cause temporary or medically reversible health consequences.
View the official FDA enforcement record (openFDA) ↗
- Official recall ID
- D-0499-2026
- Brand
- SCOPE HEALTH
- Classification
- Class II
- Recall status
- Ongoing
- Initiated
- Voluntary: Firm initiated
Description
Optase Dry Eye Intense Drops (Glycerin 0.2%), packaged in 0.33 fl oz, Sterile, Manufactured for Scope Health Inc., 79 Madison Ave., 8th Floor, New York, NY 10016, USA, NDC 72972-002-01.
Affected products
Companies & origin
- Recalling firm location
- New York, NY, United States
- Firm address
- 79 Madison Avenue, 27 E 28th St, 10016-7921
Identifying details (verbatim from the notice)
- Product codes / lots
- Lot#: 8T98, 9T31, 9T32, Exp. Date: 30/04/26; 2V13, 2V14, 2V15, Exp. Date 30/06/26; 3V35, Exp. Date 31/08/26;3V36, 3V37, Exp. Date 30/09/26; 5V45, 5V46, 9V12, Exp. Date 31/03/27; 1X57, 1X70, 1X84, Exp. Date 31/05/27.
- Distribution
- Nationwide within the United States
- Firm notified the public via
- Letter
- FDA event ID
- 98802
- Recall initiated
- April 20, 2026
- FDA classified
- April 28, 2026
- FDA report date
- May 6, 2026
Source: U.S. Food & Drug Administration. This page mirrors the official public-domain record verbatim;
the linked government source is authoritative. Source last checked July 23, 2026 at 11:04 PM UTC.
Report a data error on this page